GlobalData on MSN21h
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancerThe company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback